EBRC.Z Stock Overview
EBR Systems, Inc. develops implantable systems for wireless tissue stimulation.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
EBR Systems, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.55 |
| 52 Week High | AU$0.55 |
| 52 Week Low | AU$0.32 |
| Beta | 1.0 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | 70.75% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 70.75% |
Recent News & Updates
Recent updates
Shareholder Returns
| EBRC.Z | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 0% | 0.007% | 0.7% |
| 1Y | 70.7% | -1.0% | 23.9% |
Return vs Industry: EBRC.Z exceeded the US Medical Equipment industry which returned -1.8% over the past year.
Return vs Market: EBRC.Z exceeded the US Market which returned 15.2% over the past year.
Price Volatility
| EBRC.Z volatility | |
|---|---|
| EBRC.Z Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 7.5% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: EBRC.Z has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine EBRC.Z's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | n/a | John McCutcheon | ebrsystemsinc.com |
EBR Systems, Inc. develops implantable systems for wireless tissue stimulation. The company offers WiSE cardiac resynchronization therapy system that uses a proprietary wireless technology to deliver pacing stimulation directly to the inside of the left ventricle of the heart. Its products are used to eliminate lead complications, such as placement difficulty, unintended nerve stimulation, dislodgement, extraction, and repositioning.
EBR Systems, Inc. Fundamentals Summary
| EBRC.Z fundamental statistics | |
|---|---|
| Market cap | US$120.66m |
| Earnings (TTM) | -US$33.04m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-3.6x
P/E RatioIs EBRC.Z overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EBRC.Z income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$33.04m |
| Earnings | -US$33.04m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.11 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 88.3% |
How did EBRC.Z perform over the long term?
See historical performance and comparison